International Edition
Latest News
Health

Clinicians Attribute Movement Disorder to Cocaine, Delay Anti-IgLON5 Diagnosis

A 43-year-old man received an anti-IgLON5 disease diagnosis weeks after discharge because a positive serum antibody result returned after clinicians attributed his acute movement disorder to recent cocaine use, Cureus reported. The case, published in the journal’s June…

A 43-year-old man received an anti-IgLON5 disease diagnosis weeks after discharge because a positive serum antibody result returned after clinicians attributed his acute movement disorder to recent cocaine use, Cureus reported.

The case, published in the journal’s June 2024 issue, illustrates how substance exposure can mask a treatable autoimmune neurological condition that sits between autoimmune and neurodegenerative disease. Anti-IgLON5 disease, first described in 2014, is defined by antibodies against a neuronal cell adhesion molecule and a distinctive tauopathy affecting the hypothalamus and brainstem tegmentum. Patients carry a strong genetic association with HLA-DRB110:01 and HLA-DQB105:01 alleles.

The patient presented to a hospital with transient left-sided numbness, dysarthria, and word-finding difficulty. Examination revealed grade 2 ptosis and choreiform movements of the hands, feet, and face. Neuroimaging, electroencephalography, metabolic panels, and toxicology screening were unremarkable. A serum autoimmune antibody panel was sent.

During the admission, the patient disclosed recent cocaine use. His movements acutely worsened, showing spontaneous nonrhythmic limb jerks consistent with myoclonus. Clinicians attributed the exacerbation to a substance-induced movement disorder and discharged him while the antibody panel remained pending.

Seventeen days later, the serum result returned positive for IgLON5 antibodies at a titer of 1:1920. The patient was readmitted. A detailed history then uncovered a three-year progression of sleep disturbance, a prior home sleep study showing moderate obstructive sleep apnea, and months of nocturnal choreiform movements with vocalization and dream enactment. Lumbar puncture confirmed IgLON5 antibodies in cerebrospinal fluid at 1:128.

Paired serum and CSF testing is preferred when clinical suspicion is high. In the original clinical series of 16 patients with paired samples, 14 had antibodies in both compartments while two had antibodies in serum only, both presenting with a progressive supranuclear palsy-like phenotype. A negative result in one compartment does not exclude the diagnosis.

The patient received intravenous methylprednisolone 1 g daily for three days followed by a five-day course of intravenous immunoglobulin (IVIG). By day 21, choreiform movements and abnormal nocturnal behaviors had resolved, and insomnia had substantially improved.

He was discharged on maintenance IVIG every four weeks. At a 96-day follow-up, movement, speech, and cognitive symptoms remained in remission, though insomnia persisted at three to four hours per night, attributed to encephalitis sequelae, nocturnal urinary urgency, and hypertensive headache.

Sleep dysfunction is the most characteristic feature of anti-IgLON5 disease. It comprises a non-REM parasomnia with abnormal nocturnal motor behaviors and undifferentiated sleep, REM sleep behavior disorder, and sleep-disordered breathing including obstructive sleep apnea and stridor.

Movement disorders are frequent and often multiple.

Cocaine is a recognized cause of hyperkinetic movement disorders, associated with choreoathetosis, akathisia, chorea, stereotypies, dystonia, tics, and myoclonus. It may exacerbate a pre-existing movement disorder rather than acting as its sole cause. The two etiologies can be difficult to separate at the bedside.

The phenotype overlaps substantially with multiple system atrophy (MSA), which shares dysautonomia, stridor, and sleep-disordered breathing. IgLON5 antibodies were not detected in 18 patients with clinically probable MSA with predominant parkinsonism.

Plasma phosphorylated tau-217 in this patient measured 0.116 pg/mL, within the negative reference range (≤0.185 pg/mL). This assay assesses coexisting Alzheimer-type pathology and is not informative for the brainstem tauopathy of anti-IgLON5 disease.

Why This Case Changes the Timeline

The diagnostic delay in this case stemmed from a clinical heuristic: an acute movement disorder in the setting of recent stimulant use is frequently presumed toxic. The patient’s concurrent sleep architecture disruption — chronic insomnia, OSA, and parasomnias — was not fully elicited until after the antibody result forced a second look.

That history, had it been obtained earlier, aligns with the disease’s core phenotype: a 2023 systematic review of 285 patients found sleep abnormalities in more than three-quarters of cases, often preceding other symptoms by years.

Testing Strategy Matters

The case reinforces current guidance that paired serum and CSF testing increases diagnostic sensitivity. While 14 of 16 patients in the original series had antibodies in both compartments, the two serum-only patients shared a specific PSP-like presentation. Relying on a single compartment risks false negatives, particularly in atypical phenotypes.

Treatment Response

The patient’s rapid improvement with high-dose corticosteroids and IVIG is consistent with the immune-mediated component of the disease. However, the tauopathic neurodegeneration — concentrated in the hypothalamus and brainstem — may limit full recovery of sleep-wake regulation, as suggested by his persistent insomnia at follow-up. Maintenance IVIG every four weeks continues.

Differential Diagnosis

Distinguishing anti-IgLON5 disease from MSA remains a clinical challenge. Both present with stridor, sleep-disordered breathing, and autonomic features. The absence of severe orthostatic hypotension, predominant parkinsonism, or cerebellar ataxia weighs against MSA. The presence of IgLON5 antibodies — absent in a series of 18 probable MSA-p patients — provides a definitive biomarker when clinical features overlap.

What is anti-IgLON5 disease and how is it diagnosed?

What is anti-IgLON5 disease?

Anti-IgLON5 disease is a rare neurological disorder characterized by autoantibodies against IgLON5, a neuronal cell adhesion molecule. It combines features of autoimmune encephalitis and neurodegenerative tauopathy, with a characteristic sleep disorder, movement disorders, bulbar dysfunction, and cognitive impairment.

How is it diagnosed?

Diagnosis relies on detecting IgLON5 antibodies in serum or cerebrospinal fluid, ideally both. Paired testing is recommended because antibodies may be present in only one compartment. Clinical features — especially the combination of sleep dysfunction, movement disorders, and bulbar symptoms — guide testing.

Can cocaine use cause a similar presentation?

Cocaine can cause acute hyperkinetic movement disorders including chorea, myoclonus, and akathisia. It may also exacerbate a pre-existing movement disorder. In this case, recent cocaine use initially obscured the underlying autoimmune diagnosis.

What treatments are used?

First-line immunotherapy typically includes corticosteroids, IVIG, or plasma exchange. Some patients require maintenance immunosuppression. Response varies; sleep and movement symptoms often improve, but neurodegenerative tau pathology may limit full recovery.

How does it differ from multiple system atrophy?

Both disorders feature sleep-disordered breathing, stridor, and autonomic dysfunction. Anti-IgLON5 disease typically lacks the severe orthostatic hypotension, predominant parkinsonism, or cerebellar ataxia that characterize MSA. IgLON5 antibodies are not found in MSA.

About the author: Health Desk

Health Desk at Archynewsy.